Harrington Heart & Vascular Institute

Monday, December 10, 2018

University Hospitals’ Richard Josephson, MS, MD, leads national effort to bolster cardiac rehab

CLEVELAND – Richard Josephson, MS, MD, a University Hospitals Cleveland Medical Center cardiologist, leads a national program to increase the knowledge and engagement of physicians regarding cardiac rehabilitation.
 
Dr. Josephson, and moreover, University Hospitals, is recognized as a national leader in the field. As a result, the American College of Cardiology (ACC) selected Dr. Josephson to organize, develop and implement a first-of-its-kind and transformational web-based educational program.
 
The effort is being backed by the Centers for Disease Control (CDC) and Centers for Medicare and Medicaid Services (CMS) via their important “Million Hearts” program, a government-funded organization trying to raise awareness about prevention and rehabilitation in an effort to lower the burden of cardiovascular disease and related death.


Friday, November 30, 2018

Heather Gornik, MD, joins University Hospitals as co-director of Harrington Heart & Vascular Institute’s Vascular Center

CLEVELAND – Heather Gornik, MD, has been named co-director of the Vascular Center at University Hospitals Harrington Heart & Vascular Institute.
 
Dr. Gornik, a cardiologist and vascular medicine specialist, completed medical school at the University of Chicago followed by internal medicine, cardiology, and vascular medicine training at Brigham & Women’s Hospital, Harvard Medical School in Boston where she also served as chief medical resident. 
 
She is an internationally recognized expert in the care of complex vascular diseases, particularly fibromuscular dysplasia (FMD), an uncommon disease of the arteries that can lead to narrowing, aneurysm and dissection.


Tuesday, November 20, 2018

University Hospitals Physician Receives Major Grant for Alzheimer’s Research

CLEVELAND - Could our blood hold the molecular secrets to a fountain of youth, preventing age-related brain disorders? Can targeting red blood cells and blood vessels keep our brains healthy and prevent dementia?
 
Mukesh K. Jain, MD, Chief Scientific Officer for University Hospitals and UH Harrington Discovery Institute (HDI) and Chief Research Officer, UH Harrington Heart & Vascular Institute, will lead a multidisciplinary team of notable researchers from across the country to help answer those questions.


Wednesday, August 22, 2018

University Hospitals recruits talented geneticist to join Harrington Discovery Institute

CLEVELAND – University Hospitals has recruited Atul Chopra, MD, PhD, to join Harrington Discovery Institute—part of The Harrington Project for Discovery & Development—at University Hospitals.
 
Dr. Chopra will serve as Investigator, Harrington Discovery Institute and Associate Director of the Harrington Rare Disease Program, which seeks to advance breakthrough research into novel treatments for rare diseases. In the U.S., rare disease is defined as one that affects less than 200,000 people and very often has no meaningful treatment. Dr. Chopra also joins University Hospitals as a faculty member in the Department of Medicine and Department of Genetics.
 
“Dr. Chopra is a young physician-scientist of great promise, having already made important discoveries in the field of genetics,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute. “Dr. Chopra will help us expand our rare disease program here and abroad so that we can support discoveries with greatest potential for impact in the fight against rare diseases.”


Thursday, March 22, 2018

University Hospitals valve and structural heart team performs first transcatheter mitral valve replacement in Ohio

CLEVELAND – University Hospitals Harrington Heart & Vascular Institute officially opened the APOLLO trial today implanting the Intrepid transcatheter mitral valve replacement system on the first patient involved in the study.

Drs. Alan Markowitz and Guilherme F. Attizzani performed the first procedure in the state of Ohio.

As part of the APOLLO trial, UH patients with severe symptomatic mitral regurgitation will have the opportunity to be randomized to receive either conventional open-heart mitral valve replacement surgery or an investigational transcatheter mitral valve replacement (TMVR). In addition, patients who are not good surgical candidates could have the opportunity of being treated with TMVR.


  • News Media Access



  • Register
  • Forgot My Password
  • Search:




    Advanced Search

  • Subscribe To Our Latest News

    Subscribe to University Hospitals' RSS Feeds or Email Alerts to get our latest news.

    University Hospitals RSS Feed  University Hospitals Email Alerts
  • Twitter

    Must select a Twitter Account for Rail Gadget in Twitter Tool.

You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.